Trestle Biotherapeutics

Executive Summary

Trestle Biotherapeutics is a private tissue engineering company headquartered in San Diego, focused on developing transformative therapies for kidney disease and ultimately other organ failures. Founded in 2006, the company has advanced to Phase 2 clinical development, leveraging its proprietary platform to create regenerative solutions that address the significant unmet need in end-stage renal disease. With a mission to improve the lives of millions suffering from organ failure, Trestle aims to deliver a bioengineered kidney replacement or repair therapy that could reduce dependence on dialysis and transplantation. The company's approach combines cellular engineering, biomaterials, and vascularization techniques to construct functional renal tissue. While financial details and specific pipeline assets are not publicly disclosed, Trestle's long development timeline and Phase 2 status suggest meaningful progress toward clinical validation. The success of its lead program could position the company as a pioneer in organ regeneration, though significant technical and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Trial Interim Data Readout60% success
• TBDSeries B Financing Round70% success
• TBDStrategic Partnership for Kidney Disease Program50% success